Something else? Ask Aunt Vadge – bottom left of your screen!
If you have adenomyosis, you already know the deal: heavy, dragging periods, pain that arrives like clockwork, and a treatment list that mostly means hormones, the pill, or eventually surgery. This new pilot trial testing a vaginal medication that is not a contraceptive is worth checking out.
Researchers in Iran ran a small randomised controlled trial of vaginal bromocriptine in women with adenomyosis. The participants experienced less pain, lighter bleeding, shorter periods, and more regular cycles.1
It’s early and small, and needs larger trials before anyone gets excited at the pharmacy, but it points to a different way of treating one of the most under-served conditions in gynaecology.
What is adenomyosis, and why is it so hard to treat?
Adenomyosis is when tissue similar to the lining of the womb grows into the muscular wall of the uterus itself. The wall thickens, the uterus often enlarges, and periods get heavy and painful.5
Adenomyosis is a close cousin of endometriosis, where similar tissue grows outside the uterus instead. The two often travel together, but adenomyosis is the one more likely to cause genuinely heavy bleeding and iron-deficiency anaemia.
The frustrating part is treatment. Current options are progestins, gonadotropin-releasing hormone agonists, and oral contraceptives. These medicines work modestly at best, and many people cannot tolerate the side effects.1 Short of a hysterectomy, there has not been much that is both effective and easy to live with.
What did the vaginal bromocriptine trial find?
The trial enrolled 64 women with adenomyosis and heavy menstrual bleeding, splitting them evenly into two groups of 32.1
One group used vaginal bromocriptine, starting at 2.5 mg once daily and moving to twice daily from the second week. The comparison group got the usual routine care: mefenamic acid (an anti-inflammatory painkiller) plus oral contraceptive pills. Treatment ran for three months, with a follow-up a month later.1
Everyone finished the study, which is unusual and reassuring in itself. After treatment, the bromocriptine group reported:
- Significantly lower period pain scores
- Significantly less menstrual blood loss
- Shorter periods
- More regular cycles – 75% had regular cycles afterwards, compared with only one in four in the routine-care group
A regression analysis confirmed that bromocriptine itself was linked to the drop in menstrual bleeding, even after accounting for other factors. Thicker womb lining and more myometrial cysts were tied to heavier bleeding, which fits what we already know about the condition.1
Why would a Parkinson’s drug help your period?
Bromocriptine is a dopamine agonist. It has been around for decades, used for high prolactin levels, prolactinomas, Parkinson’s disease, and even some metabolic conditions.1 So what is it doing anywhere near a uterus?
The link is a hormone called prolactin. Evidence suggests prolactin signalling is tied up in how adenomyosis develops and progresses.3 In mouse studies, blocking dopamine triggered adenomyosis, while giving bromocriptine completely suppressed it.3
More recent work has gone further, identifying the prolactin receptor as a genuine therapeutic target in adenomyosis using single-cell sequencing.2 In other words, the prolactin angle is not a fluke – it is becoming one of the more interesting threads in adenomyosis research.
Bromocriptine lowers prolactin, and that appears to calm the overgrowth and inflammation driving the symptoms.
Why give it vaginally?
Taken by mouth, bromocriptine is notorious for nausea and other gut upset. Delivering it vaginally sidesteps the digestive tract, which improves tolerability while still lowering prolactin effectively.1 It is the same logic behind a lot of vaginal medications: get the drug where it needs to go with fewer whole-body side effects.
This is not the first time vaginal bromocriptine has shown promise here, either. An earlier pilot study found it improved pain, bleeding, and quality of life in women with adenomyosis.4 The new trial adds a controlled comparison, which makes the signal more convincing.
How excited should we actually be?
Cautiously. This is a pilot trial, and the researchers are upfront about its limits.
The follow-up was short, at only a few months. Pain was measured on a self-reported scale, which is subjective. And the two groups were not strictly comparable: the bromocriptine group received bromocriptine alone, while the control group got two different routine treatments. That makes it harder to pin every difference squarely on the bromocriptine.1
There were also no long-term imaging or biochemical analyses to show what was happening inside the uterus over time.
So this is a promising early signal, not a finished answer. What it does is justify larger, longer, better-controlled trials – and for a condition with so few good options, that alone is meaningful.
What this means for you
If you have adenomyosis, this is not something you can ask for at the chemist tomorrow. Vaginal bromocriptine for adenomyosis is still investigational, and any use would need to be supervised by a doctor who knows your full history.1
But it is worth knowing about. The research pipeline for adenomyosis and heavy periods is finally moving beyond the same handful of hormonal options, and non-contraceptive, vaginally delivered approaches are part of that shift.
In the meantime, if heavy bleeding is leaving you exhausted, it is worth checking your iron levels – chronic heavy periods are a common cause of iron-deficiency anaemia, and that is very treatable. Supporting your overall pelvic and vaginal health while you and your doctor work out a plan is never wasted effort.
If you are not sure whether your heavy or painful periods are adenomyosis, endometriosis, or something else, that is a conversation for a knowledgeable practitioner and the right imaging. Getting a name for what is happening is the first real step.
Frequently asked questions
Is bromocriptine a hormone or a contraceptive?
No. Bromocriptine is a dopamine agonist that lowers prolactin levels. It is not a hormonal contraceptive, which is part of what makes this research interesting for people who cannot or do not want to use the pill.1
Can I get vaginal bromocriptine for my adenomyosis now?
Not as a standard treatment. It remains investigational for adenomyosis and would only be considered under specialist medical supervision. The current evidence comes from small pilot trials.1
What is the difference between adenomyosis and endometriosis?
In adenomyosis, womb-lining-like tissue grows into the muscular wall of the uterus. In endometriosis, similar tissue grows outside the uterus. They often overlap, but adenomyosis is more strongly linked to heavy menstrual bleeding.5
How does lowering prolactin help heavy periods?
Prolactin signalling appears to drive some of the tissue overgrowth and inflammation behind adenomyosis. Lowering prolactin with a dopamine agonist like bromocriptine seems to calm that process, which may reduce bleeding and pain.2
Why was the drug given vaginally rather than as a tablet?
Oral bromocriptine commonly causes nausea and gut upset. Vaginal delivery avoids the digestive tract, improving tolerability while still lowering prolactin effectively.1
Related Posts
References
- Hakimi P, Eghbali E, Alborzi M, Azizi H. The impact of vaginal bromocriptine on reducing pain and menstrual bleeding in women with adenomyosis: a randomized controlled trial. Scientific Reports. 2026. Full text
- Wang R, et al. Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis. Signal Transduction and Targeted Therapy. 2025. Full text
- Auriemma RS, Del Vecchio G, Scairati R, et al. The interplay between prolactin and reproductive system: focus on uterine pathophysiology. Frontiers in Endocrinology. 2020;11:594370. Full text
- Andersson JK, Khan Z, Weaver AL, et al. Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: a pilot study. Acta Obstetricia et Gynecologica Scandinavica. 2019;98(10):1341–1350. Full text
- Habiba M, Guo SW, Benagiano G. Adenomyosis and abnormal uterine bleeding: review of the evidence. Biomolecules. 2024;14(6):616. Full text
